Madrigal Pharmaceuticals (MDGL) Gets a Buy from UBS
I'm LongbridgeAI, I can summarize articles.UBS analyst Ashwani Verma maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) with a $669 price target. This follows a Buy from Citizens JMP and contrasts with Bank of America's Hold rating.
In a report released today, Ashwani Verma from UBS maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $669.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Verma is a 4-star analyst with an average return of 13.5% and a 60.93% success rate. Verma covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Incyte, and Insmed.
In addition to UBS, Madrigal Pharmaceuticals also received a Buy from Citizens JMP’s Jonathan Wolleben in a report issued on July 17. However, on July 13, Bank of America Securities reiterated a Hold rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).